Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORBIT-EXPANSE long-term safety and efficacy of Navenibart in hereditary angioedema
jRCT2071260041Phase 3Recruiting
- Sponsor
- Astria Therapeutics
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of navenibart in hereditary angioedema (HAE) (3 arms), sponsored by Astria Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs). Started Jun 2026; status: recruiting.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2071260041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260041.